{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:08:45Z","timestamp":1789556925204,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Radiofrequency ablation (RFA) is a relatively novel, increasingly popular treatment option for leiomyomas. We studied medical device\u2013related reports of leiomyoma RFA devices to determine whether there are emerging device-related issues. The Food and Drug Administration\u2019s Manufacturer and User Facility Device Experience (MAUDE) database was queried from 2012 through November 2022. Sixty unique reports, including adverse events and device malfunctions, were analyzed for both laparoscopic and transcervical RFA devices. Forty-three injury reports were reviewed. The most common adverse event was infection. Of the injury cases, 34.9% required additional surgical intervention. Although the details of each event are limited, these reports highlight the importance of postmarket surveillance of new technologies and the necessity of improving the current system of implementation and monitoring.<\/jats:p>","DOI":"10.1097\/aog.0000000000005213","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T10:15:34Z","timestamp":1687601734000},"page":"147-150","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Radiofrequency Ablation for Treatment of Leiomyomas"],"prefix":"10.1097","volume":"142","author":[{"given":"Riley J.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Puma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Latham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Kho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13669-017-0194-2","article-title":"A new paradigm for uterine fibroid treatment: transcervical, intrauterine sonography-guided radiofrequency ablation of uterine fibroids with the sonata system","volume":"6","author":"Toub","year":"2017","journal-title":"Curr Obstet Gynecol Rep"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"500.e1","DOI":"10.1016\/j.ajog.2016.12.177","article-title":"Periprocedural outcomes comparing fibroid embolization and focused ultrasound: a randomized controlled trial and comprehensive cohort analysis","volume":"216","author":"Barnard","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jmig.2019.06.009","article-title":"Case series of reproductive outcomes after laparoscopic radiofrequency ablation of symptomatic myomas","volume":"27","author":"Berman","year":"2020","journal-title":"J Minim Invasive Gynecol"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jmig.2019.07.025","article-title":"Laparoscopic radiofrequency ablation of uterine leiomyomas: clinical outcomes during early adoption into surgical practice","volume":"27","author":"Jacoby","year":"2020","journal-title":"J Minim Invasive Gynecol"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"e2020.00050","DOI":"10.4293\/JSLS.2020.00050","article-title":"Post-market safety of laparoscopic ultrasound-guided radiofrequency ablation","volume":"24","author":"Yu","year":"2020","journal-title":"JSLS"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/CEOR.S155038","article-title":"Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada","volume":"10","author":"Rattray","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2147\/IJWH.S119265","article-title":"Surgeons' early experience with the Acessa\u2122 procedure: gaining proficiency with new technology","volume":"8","author":"Braun","year":"2016","journal-title":"Int J Womens Health"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jmig.2022.06.006","article-title":"Postoperative uterine necrosis and peritonitis following laparoscopic radiofrequency myoma ablation","volume":"29","author":"Lin","year":"2022","journal-title":"J Minim Invasive Gynecol"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/AOG.0b013e31828b7962","article-title":"Outpatient procedure for the treatment and relief of symptomatic uterine myomas","volume":"121","author":"Chudnoff","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/GRF.0b013e318161e657","article-title":"Introduction to the MAUDE database","volume":"51","author":"Gurtcheff","year":"2008","journal-title":"Clin Obstet Gynecol"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/AOG.0000000000002785","article-title":"Moving toward individualized medicine for uterine leiomyomas","volume":"132","author":"Laughlin-Tommaso","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/DSS.0000000000002832","article-title":"Barriers to reporting: limitations of the MAUDE database","volume":"47","author":"Sawaya","year":"2021","journal-title":"Dermatol Surg"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/AOG.0000000000003766","article-title":"Assessing and adopting new medical devices for obstetric and gynecologic care. ACOG Committee Opinion No. 801. American College of Obstetricians and Gynecologists","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/SLA.0000000000002794","article-title":"No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations","volume":"269","author":"Hirst","year":"2019","journal-title":"Ann Surg"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:00:45Z","timestamp":1789556445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005213"}},"subtitle":["Review of the Manufacturer and User Facility Device Experience (MAUDE) Database"],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005213","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"2023-02-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}